Kuros Biosciences 9M 2026 EBITDA jumps 81% to USD 13.5 million
Kuros Biosciences’ Group EBITDA jumped 81% year-over-year to USD 13.5 million in the first nine months of 2026. Total Medical Device sales climbed 40% year-over-year to USD 141.8 million. Its Alpharetta, Georgia, facility began commercial production of MagnetOs bone graft in October 2026, establishing dual-site manufac